Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes "NICE"


Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- 1. Subjects between 30 and 80 years.
- 2. ICD-10 and CT/MRI criteria for acute cerebral infarction.
- 3. Stroke within 7 days after onset.
- 4.based on years of education correction.MMSE>17(illiteracy),MMSE>20(primary school),MMSE>24(others)
- 5. MoCA≤26 at baseline.
- 6.Hachinski ischemic score ≥7 at baseline.
- 7.Expected good compliance to study.
- 8.Informed consent signed.

Exclusion Criteria

- 1.Diagnosis of schizophrenia, major anxiety syndrome, major depression.
- 2.Alzheimer disease, Parkinson disease, Huntington disease, and fronto-temporal dementia.
- 3.Dementia caused by (e.g., central nervous system trauma, tumor, infections, metabolic disorders, normal pressure hydrocephalus, lack of folic acid or vitamin B12, or thyroid hormone deficiency).
- 4.Contraindications to dihydropyridine derivatives.
- 5.Aphasia or other diseases that affect cognitive evaluation.
- 6.Serious arrhythmias, bradycardia (<50 bpm) or tachycardia (>120 bpm); myocardial infarction within the past 6 months; blood pressure <90/60mmHg; severe renal or hepatic insufficiency; severe anemia, Hb<100g/L; severe gastrointestinal disorders; tumor.
- 7.History of epilepsy, use of the antiepileptic drugs.
- 8.CT/MRI showed neurodegenerative changes or other lesions except cerebral ischemia.